CAMEKA CAMPBELL: Open Payments
NPI 1043753437 · LONGWOOD, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,029 in 23 payments from 9 companies in 2025. Trend: 2023 $1,284 · 2024 $2,214 · 2025 $1,029
Food & beverage: $1,029
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 6 | $380 |
| ABBVIE INC. | 7 | $248 |
| Eisai Inc. | 2 | $135 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $126 |
| GlaxoSmithKline, LLC. | 2 | $44 |
| PFIZER INC. | 2 | $37 |
| Indivior Inc. | 1 | $21 |
| Novo Nordisk Inc | 1 | $21 |
| Medtronic, Inc. | 1 | $17 |
Products named: AIRSUPRA, Leqembi, CAPLYTA, VRAYLAR, FARXIGA, QULIPTA, UBRELVY, BREZTRI.
Industry payments across FL — which companies pay providers there.
